Pharmaceutical Industry Mergers & Acquisitions News
Mergers & Acquisitions
> Pharmaceutical Industry Mergers & AcquisitionsPharmaceutical Industry Mergers & Acquisitions News is an EIN News Service for global investing professionals. Constantly updated news and information about global investing.
Latest Pharmaceutical Industry Mergers & Acquisitions News
- Cannabis Science Inc. Reports on Litigation Settlement and Debt Elimination A Vote of Confidence in Dr. Melamede, and "T 2 Dec 2009 14:57 GMT
... Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, reported today that it has ... the issuance of 3,680,000 shares of common stock in settlement of the K & D ... litigation concerned provisions of the original Asset Acquisition Agreement between K & D and Cannex ...
- American International Group, Inc. (AIG) today announced that it has closed a transaction with the Federal Reserve Bank of New York 2 Dec 2009 14:52 GMT
... consummated, to pay a portion of the merger consideration for the proposed acquisition of the Company by Tilman J. The ... values increase. Leading the group were Amylin Pharmaceuticals, Vertex Pharmaceuticals, and Biogen posting share jumps ...
- Watson Completes Acquisition of Arrow Group / Combined Global Company Has: - Over $3 Billion Annual Revenue - Operations in More than 20 Countries - Strong Product Franchise and Pipeline 2 Dec 2009 14:33 GMT
... MORRISTOWN, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. today announced that it has completed the acquisition of Arrow Group for a combination of cash and stock. The purchase creates a financially strong, global specialty pharmaceutical company with over $3 billion ...
- Swedish Biovitrum prices SEK1.6bn rights issue 2 Dec 2009 14:18 GMT
... proceeds will be used to fund the takeover of local sector player Swedish Orphan International AB. ... saying it will create a niche speciality pharma company focusing on rare diseases. The agreed ... will be paid in a combination of stock (48%) and cash (52%). The cash will ...
- Virtual Health Technologies 10Q Reports 3rd Quarter Positive Income; Explains VHGI Gold Strategy (PRN) 2 Dec 2009 14:15 GMT
... at physician practices as well as the pharmaceutical industry and state and federal regulatory agencies ... concerning our operations at or by calling shareholder relations at 859-514-6982. cautions investors that none ... pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in ...
- Cannabis Science Inc. Reports on Litigation Settlement and Debt Elimination A Vote of Confidence in 2 Dec 2009 14:15 GMT
... Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, reported today that it has ... the issuance of 3,680,000 shares of common stock in settlement of the K & D ... litigation concerned provisions of the original Asset Acquisition Agreement between K & D and Cannex ...
- Virtual Health Technologies 10Q Reports 3rd Quarter Positive Income; Explains VHGI Gold Strategy 2 Dec 2009 14:11 GMT
... settlement of debt tied to the previous acquisition of one of VHGI's healthcare technology subsidiaries. ... was settled for 1,000,751 shares of VHGI stock. "We are pleased with the continued improvement ... at physician practices as well as the pharmaceutical industry and state and federal regulatory agencies ...
- ONE Bio Obtains Key Certification Allowing for Increased Production of Highly Demanded Botanical Extracts (MRW) 2 Dec 2009 13:53 GMT
... beverages. ONE's growth plan targets an aggressive acquisition driven strategy supported by strong organic growth. ... downstream products ranging from plant indigenous medicine, pharmaceutical intermediates to a long list of eco-friendly ... business, our financial results, and the company's stock price. These risks and other factors are ...
- Cannabis Science Inc. Reports on Litigation Settlement and Debt Elimination A Vote of Confidence in Dr. Melamede, and "The Huge Potential of Our Company' 2 Dec 2009 13:51 GMT
... Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, reported today that it has ... the issuance of 3,680,000 shares of common stock in settlement of the K & D ... litigation concerned provisions of the original Asset Acquisition Agreement between K & D and Cannex ...
- ONE Bio Obtains Key Certification Allowing for Increased Production of Highly Demanded Botanical Extracts 2 Dec 2009 13:51 GMT
... beverages. ONE's growth plan targets an aggressive acquisition driven strategy supported by strong organic growth. ... downstream products ranging from plant indigenous medicine, pharmaceutical intermediates to a long list of eco-friendly ... business, our financial results, and the company's stock price. These risks and other factors are ...
- Cannabis Science Inc. Reports on Litigation Settlement and Debt Elimination A Vote of Confidence in Dr. Melamede, and "The Huge Potential of Our Company" 2 Dec 2009 13:50 GMT
... 2009 (BUSINESS WIRE) -- ), an emerging pharmaceutical cannabis company, reported today that it has ... the issuance of 3,680,000 shares of common stock in settlement of the K & D ... litigation concerned provisions of the original Asset Acquisition Agreement between K & D and Cannex ...
- www.StockMarketingInc.com: Check Us Out Now!! We Are Hot!! CVAT,VSYM,SGCA,HYGS,ALXN,THQ:: Sign Up Now!! 2 Dec 2009 13:37 GMT
... to profitability and later focusing on strategic acquisitions to increase acreage, reserves, and daily production. ... Company's profile with the investment community, develop merger and acquisition strategies, and further identify oil and ... CHESHIRE, Conn., Dec 02, 2009 -- Alexion Pharmaceuticals, Inc. (Nasdaq: ) today provided updates on ...
- Seasoned Clinical Development Expert Joins Opexa to Lead Tovaxin Development in Multiple Sclerosis 2 Dec 2009 13:37 GMT
... she managed and successfully grew until its acquisition by inVentiv Health (NASDAQ:VTIV) in 2006. She ... Clinical Research and Medical Affairs at Elan Pharmaceuticals. Dr. McGuire has agreed to deepen her ... hire and retain skilled personnel, our volatile stock price, and other risks detailed in our ...
- Research and Markets: The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2 Dec 2009 13:31 GMT
... reviews the competitive landscape in terms of mergers and acquisitions, pipeline products and technology offerings. In-depth analysis ... as the higher volume of diseased and pharmacotherapy treated population. CNS Therapeutics Market, Global, Key ...
- Seasoned Clinical Development Expert Joins Opexa to Lead Tovaxin® Development in Multiple Sclerosis 2 Dec 2009 13:31 GMT
... she managed and successfully grew until its acquisition by inVentiv Health (NASDAQ:VTIV) in 2006. She ... Clinical Research and Medical Affairs at Elan Pharmaceuticals. Dr. McGuire has agreed to deepen her ... hire and retain skilled personnel, our volatile stock price, and other risks detailed in our ...
Powered by 
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
|
a digital news provider
abcnews.go.com:
moneyweek.com:
reuters.com: